Evidence mapPaperPMID 39468616Full record

ReviewStem cell research & therapy2024

Emerging role and function of Hippo-YAP/TAZ signaling pathway in musculoskeletal disorders.

Juanjuan Han, Jiale Zhang, Xiaoyi Zhang, Wenxin Luo, Lifei Liu, Yuqing Zhu, Qingfeng Liu, Xin-An Zhang

Abstract readReview
In one paragraph

Review in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Epigenetic Regulation of RUNX2 in Bone Mechanobiology.Results and problems in cell differentiation · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Juanjuan Han *College of Exercise and Health, Shenyang Sport University, Shenyang, 110100, China.
Jiale Zhang *College of Exercise and Health, Shenyang Sport University, Shenyang, 110100, China.
Xiaoyi ZhangCollege of Second Clinical Medical, China Medical University, Shenyang, 110122, China.
Wenxin LuoCollege of Exercise and Health, Shenyang Sport University, Shenyang, 110100, China.
Lifei LiuDepartment of Rehabilitation, The People's Hospital of Liaoning Province, Shenyang, 110016, China.
Yuqing ZhuCollege of Exercise and Health, Shenyang Sport University, Shenyang, 110100, China.
Qingfeng LiuDepartment of General Surgery, Jinqiu Hospital of Liaoning Province, Shenyang, 110016, China.
Xin-An ZhangCollege of Exercise and Health, Shenyang Sport University, Shenyang, 110100, China. Zhangxa2725@163.com.

Funding

National Natural Science Foundation of China No. 32371184
6 · The paper itself

Abstract

Hippo pathway is an evolutionarily conservative key pathway that regulates organ size and tissue regeneration by regulating cell proliferation, differentiation and apoptosis. Yes-associated protein 1 (YAP)/ WW domain-containing transcription regulator 1 (TAZ) serves as a pivotal transcription factor within the Hippo signaling pathway, which undergoes negative regulation by the Hippo pathway. The expression of YAP/TAZ affects various biological processes, including differentiation of osteoblasts (OB) and osteoclasts (OC), cartilage homeostasis, skeletal muscle development, regeneration and quality maintenance. At the same time, the dysregulation of the Hippo pathway can concurrently contribute to the development of various musculoskeletal disorders, including bone tumors, osteoporosis (OP), osteoarthritis (OA), intervertebral disc degeneration (IDD), muscular dystrophy, and rhabdomyosarcoma (RMS). Therefore, targeting the Hippo pathway has emerged as a promising therapeutic strategy for the treatment of musculoskeletal disorders. The focus of this review is to elucidate the mechanisms by which the Hippo pathway maintains homeostasis in bone, cartilage, and skeletal muscle, while also providing a comprehensive summary of the pivotal role played by core components of this pathway in musculoskeletal diseases. The efficacy and feasibility of Hippo pathway-related drugs for targeted therapy of musculoskeletal diseases are also discussed in our study. These endeavors offer novel insights into the application of Hippo signaling in musculoskeletal disorders, providing effective therapeutic targets and potential drug candidates for treating such conditions.

Indexed as

Hippo Signaling PathwayMusculoskeletal DiseasesSignal TransductionAdaptor Proteins, Signal TransducingAnimalsCell DifferentiationHumansIntervertebral Disc DegenerationOsteoarthritisProtein Serine-Threonine KinasesTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingProtein Serine-Threonine KinasesTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanYAP1 protein, humanYAP-Signaling ProteinsCartilageHippoMusculoskeletal diseasesOsteoblastOsteoclastSkeletal muscleYAP/TAZ

Identifiers

PMID39468616
PMCPMC11520482

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.